Symposium 9: Targeting guanylyl cyclases for the treatment of cardiovascular disorders
Tracks
Track 1
| Wednesday, July 15, 2026 |
| 11:15 AM - 1:15 PM |
Details
Nitric oxide and natriuretic peptide -sensitive guanylyl cyclases (GCs) are cyclic guanosine-3’,5’-monophosphate (cGMP)-generating catalytic receptors that play key, complimentary roles in regulating cardiac and vascular homeostasis. Contemporary advances in the understating of the physiological and pathophysiological function(s) of GCs have led to the development of a number of new medicines targeting this family of enzymes for the treatment of a wide variety of cardiovascular diseases, including erectile dysfunction, pulmonary hypertension (PH), heart failure with reduced (HFrEF) and preserved (HFpEF) ejection fraction, and cardiometabolic disease. This symposium will comprise internationally-leading experts in the field who will update on cutting-edge advances in the pre-clinical and clinical arena, with respect to both elucidating novel GC-dependent signalling pathways in the cardiovascular system and new GC-targeted therapies for cardiac and vascular disorders.
Speaker
A/Prof Valentina Cannone
University of Parma
MANP: a natriuretic peptide-based therapy for cardiometabolic disease
Biography
Prof. Cannone is Associate Professor of Internal Medicine at the University of Parma, Parma, Italy, Research Collaborator at the Cardiorenal Research Laboratory at Mayo Clinic, Rochester, MN, USA and Scientific Advisor for E-STAR Biotech Company.
Prof. Cannone’s translational research studies have been focused on genetics and cardiometabolic properties of natriuretic peptides. More specifically, Prof. Cannone has analyzed the clinical phenotype and risk associated with genetic variants of natriuretic peptides. In animal model of hypertension and metabolic syndrome, Prof. Cannone has also investigated the cardiovascular and metabolic actions of MANP, which is a novel ANP-like peptide designed at Mayo Clinic. Importantly, funded by the American Heart Association and Mayo Clinic Department of Cardiovascular Medicine, Prof. Cannone has also served as the Principal Investigator in a clinical study focused on evaluating the acute cardiometabolic action of MANP in subjects with hypertension and metabolic syndrome. As Scientific Advisor, Prof. Cannone is currently involved in a phase II clinical trial aimed to test MANP in difficult to control/resistant hypertension.
Prof. Cannone has been the recipient of awards from the Heart Failure Society of America and the Italian Society of Arterial Hypertension.
Prof. Cannone’s long-term goal is the development of a natriuretic peptide-based therapy for cardiometabolic disease.
Dr Aisah Aubdool
Queen Mary University of London
Role of C-type natriuretic peptide in the pathogenesis of aortic aneurysm
Biography
Aisah is a Lecturer in Cardiovascular Pharmacology at Queen Mary University of London. She graduated with a BSc (Hons) in Pharmacology before gaining her PhD from King’s College London, under the mentorship of Professor Susan D Brain. Aisah moved to William Harvey Research Institute in 2016 as a postdoctoral research fellow in the lab of Professor Adrian Hobbs. Aisah’s research focuses on studying the role of C-type natriuretic peptide in vascular remodelling and aortic aneurysms. She was the Chair for the IUPHAR ECR Committee (2018-2022). Aisah is a Senior Editor for Pharmacology Matters, BPS Ambassador regional coordinator and member of BPS Engagement Committee.
Session chair
Adrian Hobbs
Queen Mary University Of London
Anida Velagic
Monash Institute of Pharmaceutical Sciences
